

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYDARBD (subcut)

(Page 1 of 3)

DOCTOR'S ORDERS	Ht	cm	Wt	kg	BSA	m²
REMINDER: Please ensure drug allergies a	and previous bleo	mycin are	docum	ented on the	e Allerg	y & Alert Form
DATE: To b	pe given:			Cycle #:		
Date of Previous Cycle:						
****Ensure Red Blood Cell Phenotype and Gr Delay treatment week(s) CBC & Diff day of treatment Proceed with all medications for entire cycle a 109/L, platelets greater than or equal to 50 a and eGFR or creatinine clearance per protection.	s written, if within 9 x 10⁹/L, total biliru	96 hours of	Day 1: <i>I</i>	ANC greater	than o	
Dose modification for: Hematology: Proceed with treatment based on blood work f		_ 🗌 Oti	ner Toxi	icity:		
CHEMOTHERAPY: CYCLOPHOSPHAMIDE - Cycles 1 to cyclophosphamide 500 mg PO once week OR cyclophosphamide mg PO once week OR cyclophosphamide 50 mg PO once in the	ekly in the morning	on Days 1,	8, 15, a	and 22. Dispe	spense ₋	cycles.
BORTEZOMIB – Cycles 1 to 8 • Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily bortezomib □1.5 mg/m² or □1.3 mg/m² or □1 mg/m² or □0.7 mg/m² or □0.5 mg/m² (select one) x BSA =mg subcutaneous injection weekly on Days 1, 8, 15, and 22						
STEROID: RN to use patient's therapeutic steroid (if applicable) as pre-med for daratumumab - refer to protocol Cycles 1 to 8 (Cycle 9 onwards optional) dexamethasone 40 mg or 20 mg PO once weekly on Days 1, 8, 15, and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, OR dexamethasonemg PO once weekly on Days 1, 8, 15, and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, OR predniSONE 100 mg ormg PO once weekly on Days 1, 8, 15, and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning No steroid						
DOCTOR'S SIGNATURE:				SIGNA UC:	TURE	:



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYDARBD (subcut)

(Page 2 of 3)

DATE:					
**Have Hypersensitivity Reaction Tray and Protocol Av Insert a peripheral IV and saline lock for Cycle 1 Day 1 only for use in the event					
DARATUMUMAB					
Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily					
DARATUMUMAB PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm. dexamethasone as ordered in steroid section					
montelukast 10 mg PO prior to daratumumab on Cycle 1 Day 1					
montelukast 10 mg PO prior to each daratumumab					
acetaminophen 650 mg PO prior to each daratumumab. Repeat acetaminophen 650 mg PO every 4 hours when needed					
Select one of the following:					
☐ Ioratadine 10 mg PO prior to each daratumumab, then diphenhydrAMINE 50 n OR	ng IV every 4 hours when needed				
☐ diphenhydrAMINE 50 mg ☐ PO or ☐ IV prior to each daratumumab. Repeat diphenhydrAMINE 50 mg IV every 4 hours when needed					
daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen CYCLE # 2, Days 1, 8, 15 and 22: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen CYCLES 3 to 4, Days 1 and 15: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen	over 5 minutes*				
	over 3 minutes				
☐ CYCLES 5 to 8, Day 1: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes*					
☐ CYCLE 9 onwards, Day 1:					
daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen	over 5 minutes* x cycle(s) (max 3 cycles)				
*Observe patient for 1 hour after administration on Day 1 of Cycle 1 only. For patients switching from IV daratumumab, observe for 30 minutes after the first subcutaneous dose. Observation not required on subsequent doses unless requested by physician. Vital signs immediately prior to and at the end of injection, and at end of observation period of first injection only, and as needed.					
NB: During treatment with subcutaneous daratumumab, administer other subcutaneous drugs at possible	alternative injection sites whenever				
DOCTOR'S SIGNATURE:	SIGNATURE: UC:				



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYDARBD (subcut)

(Page 3 of 3)

DATE:				
RETURN APPOINTMENT ORDERS				
For Cycles 1 to 8 book chemo on Days 1, 8, 15, 22 For Cycles 9 and subsequent, book chemo on Day 1 Return in four weeks for Doctor and Cycle and Book chemo x 2 cycles. Return in twelve weeks for Doctor and Cycles, and Book chemo x 3 cycles Last Cycle. Return in week(s).				
CBC & Diff, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, LDH, random glucose, serum protein electrophoresis and serum free light chain levels every 4 weeks Urine protein electrophoresis every 4 weeks Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks Beta-2 microglobulin every 4 weeks CBC & Diff Days 8, 15, 22 Creatinine, sodium, potassium Days 8, 15, 22 Total bilirubin, ALT, alkaline phosphatase Days 8, 15, 22 Random glucose Days 8, 15, 22 Calcium, albumin Days 8, 15, 22 HBV viral load prior to next cycle See general orders sheet for additional requests Other tests: Consults				
DOCTOR'S SIGNATURE:	SIGNATURE:			
	uc.			